These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
124 related items for PubMed ID: 1699704
21. Role of Fluosol-DA 20% in prehospital resuscitation. Elliott LA, Ledgerwood AM, Lucas CE, McCoy LE, McGonigal M, Sullivan MW. Crit Care Med; 1989 Feb; 17(2):166-72. PubMed ID: 2914450 [Abstract] [Full Text] [Related]
22. Cardiovascular effects of various colloidal solutions during major abdominal surgery. Nishimura N, Hiranuma N, Sugi T. Crit Care Med; 1983 Dec; 11(12):940-2. PubMed ID: 6196154 [Abstract] [Full Text] [Related]
23. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty. Kerins DM. Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713 [No Abstract] [Full Text] [Related]
24. Use of a whole blood substitute, Fluosol-DA 20%, after massive postpartum hemorrhage. Karn KE, Ogburn PL, Julian T, Cerra FB, Hammerschmidt DE, Vercellotti G. Obstet Gynecol; 1985 Jan; 65(1):127-30. PubMed ID: 3871250 [Abstract] [Full Text] [Related]
25. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia. Kolodgie FD, Dawson AK, Roden DM, Forman MB, Virmani R. Am Heart J; 1986 Dec; 112(6):1192-201. PubMed ID: 3788766 [Abstract] [Full Text] [Related]
27. Recent studies on perfluorochemical (PFC) emulsion as an oxygen carrier in Japan. Mitsuno T, Ohyanagi H, Yokoyama K, Suyama T. Biomater Artif Cells Artif Organs; 1988 Jun; 16(1-3):365-73. PubMed ID: 3052644 [Abstract] [Full Text] [Related]
28. Effects of a transfusion with a blood substitute (Fluosol-DA, 20%). Part II: Human cerebral blood flow. Nagasawa S, Handa H, Yonekawa Y, Oda Y, Tsuda Y, Yokoyama K. Neurol Res; 1983 Jun; 5(2):19-30. PubMed ID: 6140661 [Abstract] [Full Text] [Related]
29. Development of a perfluorochemical whole blood substitute (Fluosol-DA, 20%)--an overview of clinical studies with 185 patients. Suyama T, Yokoyama K, Naito R. Prog Clin Biol Res; 1981 Jun; 55():609-28. PubMed ID: 7027272 [Abstract] [Full Text] [Related]
31. Rationale for the clinical studies of anemia treated with the perfluorochemical emulsion: Fluosol DA 20%. Tremper KK. Prog Clin Biol Res; 1983 Jun; 122():307-13. PubMed ID: 6348785 [No Abstract] [Full Text] [Related]
36. Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%. Cleman M, Jaffee CC, Wohlgelernter D. Circulation; 1986 Sep; 74(3):555-62. PubMed ID: 2943533 [Abstract] [Full Text] [Related]
37. Fluosol-DA as a red-cell substitute in acute anemia. N Engl J Med; 1986 Dec 25; 315(26):1677-8. PubMed ID: 3785341 [No Abstract] [Full Text] [Related]
38. Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services? Vox Sang; 1982 Feb 25; 42(2):97-109. PubMed ID: 7064434 [No Abstract] [Full Text] [Related]
39. Initial results of a clinical trial of Fluosol-DA 20 percent in acute cerebral ischemia. Swann KW, Ropper AH, Zervas NT. Prog Clin Biol Res; 1983 Feb 25; 122():399-404. PubMed ID: 6348787 [Abstract] [Full Text] [Related]
40. Red blood cell substitutes and artificial blood. Bowman RJ. Hum Pathol; 1983 Mar 25; 14(3):218-20. PubMed ID: 6832769 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]